Sarpogrelate: Cardiovascular and renal clinical potential

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 865-874

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

5 HT2A receptor antagonist; Animal models; Cardiovascular disease; Clinical trials; Diabetes mellitus; Renal disease; Sarpogrelate

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN; ARACHIDONIC ACID; CHELERYTHRINE; CYCLIC AMP; CYPROHEPTADINE; ENDOTHELIN 1; FENCLONINE; KETANSERIN; PADGEM PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C INHIBITOR; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SUPEROXIDE; THROMBOXANE A2; TICLOPIDINE;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BUERGER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIABETES MELLITUS; DNA SYNTHESIS INHIBITION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENANTIOMER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VALVE PROSTHESIS; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIVER DYSFUNCTION; MITOGENICITY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RESTENOSIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC SCLEROSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; MOLECULAR STRUCTURE; SUCCINATES;

EID: 3543090970     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.865     Document Type: Article

References (76)

1. DOGGRELL SA: The tole of 5-HT on the cardiovascular and renal systems and clinical potential of 5-HT modulation. Expert Opin. Investig. Drugs (2003) 12:805-823.
2. HAMAMORI Y, YOKOYAMA M, YAMADA M et al.: 5-Hydroytryptamine induced phospholipase C-mediated hydrolysis of phosphoinositides through 5-hydroxytryptamine receptors in cultures fetal mouse ventricular myocytes. Circ. Res. (1990) 66:1474-1483.
3. LAER S, REMMERS F, SCHOLZ H et al.: Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br. J. Pharmacol. (1998) 123:1182-1188.
4. KAUMANN AJ, SANDERS L, BROWN AM, MURRAY KJ, BROWN MJ: A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. (1990) 100:879-885.
5. NILSSON T, LONGMORE H, SHAW D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. (1999) 372:49-56.
6. GOLINO P, PISCIONE F, WILLERSON JT et al. Divergent effects of serotonin in coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. (1991) 324:641-648.
7. LEOSCO D, FINESCHI M, PIERLI C et al.: Intracoronary serotonin release after high-pressure coronary stenting. Am. J. Cardiol. (1999) 84:1317-1322.
8. WRIGHT L, HOMANS DC, LAXSON DD, DAI XZ, BACHE RJ: Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels. J. Am. Coll. Cardiol. (1992) 19:687-693.
9. SERRUYS PW, KLEIN W, TIJSSEN JP et al.: Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A muticenter randomized double-blind placebo-controlled trial. Circulation (1993) 88:1588-1601.
10. LEE SL, WANG WW, MOORE BJ, FANBURG BL: Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res. (1991) 68:1362-1368.
11. PAKALA R, WILLERSON JT, BENEDICT CR: Mitogenic effect of serotonin on vascular endothelial cells. Circulation (1994) 90:1919-1926.
12. DOGGRELL SA: Pharmacotherapy of intermittent claudication. Expert Opin. Pharmacother. (2001) 2:1725-1736.
13. SMULDERS YM: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc. Res. (2000) 48:23-33.
14. STEYN DW, ODENDAAL HJ: Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet (1997) 350:1267-1271.
15. BARRADAS MA, GILL DS, FONSECA VA, MIKHAILIDIS DP, DANDONA R: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur. J. Clin. Invest (1988) 18:399-404.
16. MALYSZKO H, URANO T, KNOFLER R et al.: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb. Res. (1994) 75:569-576.
17. RATTIGAN S, DORA KA, COLQUHOUN EQ, CLARK MG: Serotonin-mediated acute insulin resistance in the perfused rat hindlimb but not in incubated muscle: a role for the vascular system. Life Sci. (1993) 53:1545-1555.
18. HEAD RJ, LONGHURST PA, PANEK RL, STITZEL RE: A contrasting effect of the diabetic state upon the contractile responses of aortic preparations from the rat and rabbit Br. J. Pharmacol. (1987) 91:275-286.
19. JAMES GM, HODGSON WC: Attenuated 5-HT2 receptor-mediated responses in hindquarters of diabetic rats. Ear. J. Pharmacal. (1995) 294:109-115.
20. TURNER NC, WHITE P: Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinaemic obese Zucker rats. J. Cardiovasc. Pharmacol. (1996) 27:884-890.
21. EL-KASHEF H: Hyperglycemia increased the responsiveness of isolated rabbit pulmonary arterial rings to serotonin. Pharmacology (1996) 53:151-159.
22. BEENEN OH, MATHY MJ, PFAFFENDORF M, VAN ZWEITEN PA: Vascular responsiveness in isolated perfused kidneys of diabetic hypertensive rats. J. Hypertens. (1996) 14:1125-1130.
23. BOSTON PC, HODGSON WC: Changes in reactivity toward 5-hydroxytryptamine in the renal vasculature of the diabetic spontaneoulsy hypertensive rat. J. Hypertens. (1997) 15:769-774
24. MIRANDA FJ, ALABADI JA, LLORENS S et al.: Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. Eur. J. Pharmacol. (2002) 439:121-127.
25. WEBSTER GJ, PETCH EW, COWEN T: Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxytryptamine specific to mesenteric perivascular sympathetic nerves and without loss of nerve fibers. Exp. Neurol. (1991) 113:53-62.
26. KASHO M, SAKAI M, SASAHARA T et al.: Serotonin enhances production of type IV collagen by human mesangial cells. Kidney Int. (1998) 54:1083-1092.
27. KIKUMOTO R, HARA H, NINOMIYA K et al.: Synthesis and platelet aggregation inhibitory and antithrombotic properties of [2[(omega-aminoalkpxy)phenyl]ethyl]benzenes. J. Med. Chem. (1990) 33:1818-1823.
28. MARUYAMA K, KINAMI J, SUGITA Y et al.: MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. J. Pharmacobiodyn. (1991) 14:177-181.
29. HARA H, OSAKABE M, KITAJIMA A, TAMAO Y, KIKUMOTO R: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb. Haemost (1991) 65:415-420.
30. PERTZ H, ELZ S: In-vitro pharmacology of sarpogrelate and enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contraction in rat tail artery. J. Pharm. Pharmacol. (1995) 47:310-316.
31. NISHIO H, INOUE A, NAKATA Y: Binding affinity of sarpogrelate, a new antiplatelet agent, and metabolite for serotonin receptor subtypes. Arch. Int. Pharmacodyn. Ther. (1996) 331:189-202.
32. ISRAILOVA M, SUZUKI F, TANAKA T et al.: Binding and functional affinity of sarpogrelate, it metabolite M-1 and ketanserin for human recombinant α-1-adrenoceptor subtypes. Pharmacology (2002) 65:69-73.
33. 2A receptor ligand recognition sites in rat renal cortical and mesangial cells in culture. Gen. Pharmacol. (1999) 33:51-57.
34. NAKAMURA K, KARIYAZONO H, MORIYAMA Y et al.: Effects of sarpogrelate hydrochloride on platelet aggregation and its relation to the release of serotonin and P-selectin. Blood Coagul. Fibrinolysis (1999) 10:513-519.
35. QI R, OZAKI Y, SATOH K et al.: Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb. Res. (1996) 81:43-54.
36. NAKAMURA K, KARIYAZONO H, MASUDA H, SAKATA R, YAMADA K: Effects of sarpogrelate hydrochloride on adenosine or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul. Fibrinolysis. (2001) 12:391-397.
37. PIETRASZEK MH, TAKADA Y, TAMINATO A et al.: The effect of MCI-9042 on serotonin-induced platelet aggregation in Type 2 diabetes mellitus. Thromb. Res. (1993) 70:131-138.
38. SHOUZU A, NOMURA S, HAYAKAWAT et al.: Effect of sarpogrelate hydrochloride on platelet-derived microparticles ans various soluble adhesion molecules in diabetes mellitus. Clin. Appl. Thromb. Hemost. (2000) 6:139-143.
39. SHARMA SK, ZAHRADKA P, CHAPMAN D et al.: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J. Pharmacol. Exp. Ther. (1999) 290:1475-1481.
40. WATANABE T, PAKALA R, KATAGIRI T, BENEDICT CR: Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. J. Hypertens. (2001) 19:731-739.
41. WATANABE T, PAKALA R, KATAGIRI T, BENEDICT CR: Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J. Vasc. Res. (2001) 38:341-349.
42. SHARMA SK, DEL RIZZO DF, ZAHRADKA P et al.: Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thorac. Surg. (2001) 71:1856-1864.
43. IKEDA K, TOJO K, TOKUDOME G et al.: The effects of sarpogrelate on cardiomyocyte hypertrophy. Life Sci. 67:2991-2996.
44. ETO Y, NITTA K, UCHIDA K et al.: Anti-mitogenic effects of sarpogrelate in cultured rat mesangial cells. Life Sci. (1997) 60:PL193-PL199.
45. KASHO M, SAKAI M, SASAHARA T et al.: Serotonin enhances the production of Type IV collagen by human mesangial cells. Kidney Int. (1998) 54:1083-1092.
46. MIKAWA K, AKAMATSU H, NISHINA K et al.: The effects of sarpogrelate on superoxide production by human neutrophils. Reg. Anesth. Pain. Med. (2000) 25:181-185.
47. HARA H, KITAJIMA A, SHIMADA H, TAMAO Y: Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb. Haemost. (1991) 66:484-488.
48. 2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur. J Pharmacol. (2001) 433:157-162.
49. 2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J. Cardiovasc. Pharmacol. (2000) 35:294-301.
50. HAYASHI T, SUMI D, MATSUI-HIRAI H et al.: Sarpogrelate HCI, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis (2003) 168:23-31.
51. 2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit. Int. Angiol. (1997) 16:204-209.
52. HARA H, SHIMADA H, KITAJIMA A, TAMAO Y: Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl) phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung (1991) 41:616-620.
53. MIYATA M, ITO M, SASAJIMA T et al.: Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung (2000) 178:63-73.
54. HIRONAKA E, HONGO M, SAKAI A et al.: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc. Res. (2003) 60:692-629.
55. MIYATA M, ITO M, SASAJIMA T, OHIRA H, KASUKAWA R: Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest (2001) 119:554-561.
56. SETOGUCHI Y, OHNUKI T, RASKID M et al.: Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneous lyhypertensive rats: comparison with quinapril. Pharmacol. (2002) 64:71-75.
57. TEMSAH RM, KUMAMOTO H, TAKEDA N, DHALLA NS: Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can. J. Physiol. Pharmacol. (2001) 79:761-767.
58. 2A receptors by sarpogrelate protects the heart against myocardial infurction in rats. J. Cardiovasc. Pharmacol. Ther. (2002) 7:53-59.
59. SHIMIZU Y, MINATOGUCHI S, HASHIMOTO K et al.: The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2A receptor blocker, in rabbit hearts. J. Am. Coll. Cardiol. (2002) 40:1347-1355.
60. ICHIYANAGI N, TSUJII T, MASUDA H et al.: Changes responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction. J. Urol. (2002) 168:303-307.
61. UMRANI DN, BODIWALA DN, GOYAL RK: Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Mol. Cell. Biochem. (2003) 249:53-57.
62. CAMERON NE, COTTER MA: The effect of 5-hydoxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 367:607-614.
63. TAKISHITA E, TAKAHASHI A, HARADA N et al.: Effect of sarpogrelate, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a Type 2 diabetic rat model. J. Cardiovasc. Pharmacol. (2004) 43:266-270.
64. KANAI H, HIROMURA K, KUROIWA T et al.: Role of serotonin in nephrotoxic serum nephritis in WKY rats. J. Lab. Clin. Med. (1997) 129:557-566.
65. TANAKA T, FUJITA M, NAKAE I et al.: Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J. Am. Coll. Cardiol. (1998) 32:1982-1986.
66. KINUGAWA T, FUJITA M, LEE JD et al.: Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with anginal pectoris. Am. Heart. J. (2002) 144:E1
67. 2-receptor antagonist, improves coronary microcirculation in coronary artery disease. Clin. Cardiol. (2002) 25:28-32.
68. HORIBE E, NISHIGAKI K, MINATOGUCHI S, FUJIWARA H: Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease. Circ. J. (2004) 68:68-72.
69. FUJITA M, MIZUNO K, HO M et al.: Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart. J. (2003) 145:E16.
70. USUI A, TAKAGI Y, OHARA Y et al.: Sarpogrelate reduces mechanical hemolyus in patients with heart valve prostheses. Jpn J. Thorac. Cardiovasc. Surg. (2000) 48:769-774.
71. ISHIMURA E, NICHIZAWA Y, EMOTO M et al.: Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, in diabetic nephropathy and neuropathy. Nephron (1997) 76:227-229.
72. OGAWA S, TAKEUCHI K, SUGIMURA K et al.: The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin. Exp. Pharmacol. Physiol. (1999) 26:461-464.
73. TAKAHASHI T, YANO M, MINAMI J et al.: Sarpogrelate hydrochloride, a serotonin2A receptor antagonist reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res. Clin. Pract. (2002) 58:123-129.
74. 2 receptor antagonist. J. Dermatol. (2000) 27:643-650.
75. KATO S, KISHIRO I, MACHIDA M et al.: Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. J. Int. Med. Res. (2000) 28:258-268.
76. 2 antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb. Res. (1996) 84:445-452.